Mark R. Lackner

8.1k citations
82 papers · 4.4k · h-index 32

Impact in

  • Aging top 0.5%
    • Genetics, Aging, and Longevity in Model Organisms
  • Cancer Research top 1%
    • Cancer Genomics and Diagnostics
    • MicroRNA in disease regulation

Papers in

  • Molecular Biology 46
    • PI3K/AKT/mTOR signaling in cancer 20
    • Epigenetics and DNA Methylation 7
  • Oncology 30
    • Cancer Cells and Metastasis 7
    • HER2/EGFR in Cancer Research 7
    • Colorectal Cancer Treatments and Studies 6
Co-authors
Lukas C. Amler (23 shared papers)Carol O’Brien (21 shared papers)Jill M. Spoerke (27 shared papers)Stuart K. Kim (2 shared papers)Garret M. Hampton (22 shared papers)Elizabeth A. Punnoose (8 shared papers)Heidi Savage (12 shared papers)Timothy R. Wilson (14 shared papers)
Journals
Cancer Research (20 papers)Clinical Cancer Research (12 papers)Molecular Cancer Therapeutics (6 papers)Journal of Clinical Oncology (6 papers)Annals of Oncology (3 papers)
Partner nations
United StatesFranceUnited Kingdom

In The Last Decade

Mark R. Lackner

80 papers receiving 4.3k citations

Peers

Mark R. Lackner
Comparison fields: 5 of 108
  • Aging 365
  • Cancer Research 1.5k
  • Oncology 1.8k
  • Molecular Biology 2.6k
  • Pulmonary and Respiratory Medicine 988
Replace Paolo Nucíforo with:
Paolo Nucíforo Spain
Marta Pàez‐Ribes United Kingdom
Spencer J. Collis United Kingdom
Simone Petersen Germany
Hirotaka Osada Japan
Caterina Nardella United States
Frank Stegmeier United States
Nicholas A. Willis United States
Igor Garkavtsev United States
Kim L. Mercer United States
Mark R. Lackner relative to Paolo Nucíforo Spain Paolo Nucíforo's profile →
Citations per field
00.5×2×3×4.2×
Paolo Nucíforo · 1×
Citations per year

Countries citing papers authored by Mark R. Lackner

Since Specialization
Citations

This map shows the geographic impact of Mark R. Lackner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Lackner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Lackner more than expected).

Fields of papers citing papers by Mark R. Lackner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Lackner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Lackner. The network helps show where Mark R. Lackner may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark R. Lackner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark R. Lackner Line = papers co-authored together Mark R. Lackner links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 82 papers — load more, or switch the sort, to bring in the rest.

#Work
1
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Clinical Cancer Research ·Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd, Guy Cavet, Steve Guerrero, Kenneth Jung, Tom Januario, Heidi Savage, Elizabeth A. Punnoose, Tom Truong, Wei Zhou, Leanne Berry, Lesley Murray, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner
2009385
2
Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Clinical Cancer Research ·Elizabeth A. Punnoose, Siminder Atwal, Weiqun Liu, Rajiv Raja, Bernard M. Fine, Brett Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkall, Mark R. Lackner
2012341
3
TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer
Science Signaling ·Susanna Stinson, Mark R. Lackner, Alex Adai, Nancy Yu, Hyo‐Jin Kim, Carol O’Brien, Jill M. Spoerke, Suchit Jhunjhunwala, Zachary Boyd, Thomas Januario, Robert Newman, Yue Peng, Richard Bourgon, Zora Modrušan, Howard M. Stern, Søren Warming, Frédéric J. de Sauvage, Lukas C. Amler, Ru‐Fang Yeh, David Dornan
2011252
4
Molecular Biomarker Analyses Using Circulating Tumor Cells
PLoS ONE ·Elizabeth A. Punnoose, Siminder Atwal, Jill M. Spoerke, Heidi Savage, Ajay Pandita, Ru‐Fang Yeh, Andrea Pirzkall, Bernard M. Fine, Lukas C. Amler, Daniel S. Chen, Mark R. Lackner
2010238
5
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Nature Communications ·Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian E. Krop, Peter Schmid, Mark R. Lackner
2016219
6
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Clinical Cancer Research ·Carol O’Brien, Jeffrey J. Wallin, Deepak Sampath, Debraj GuhaThakurta, Heidi Savage, Elizabeth A. Punnoose, Jane Guan, Leanne Berry, Wei Wei Prior, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner
2010201
7
A MAP kinase homolog, mpk-1, is involved in ras-mediated induction of vulval cell fates in Caenorhabditis elegans.
Genes & Development ·Mark R. Lackner, Kerry Kornfeld, Leilani M Miller, H. Robert Horvitz, S K Kim
1994181
8
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Molecular Cancer Research ·Xiaolan Hu, Howard M. Stern, Lin Ge, Carol O’Brien, Lauren E. Haydu, Cynthia D. Honchell, Peter M. Haverty, Brock A. Peters, Thomas D. Wu, Lukas C. Amler, John Chant, David Stokoe, Mark R. Lackner, Guy Cavet
2009177
9
MAP Kinase Signaling Specificity Mediated by the LIN-1 Ets/LIN-31 WH Transcription Factor Complex during C. elegans Vulval Induction
Cell ·Patrick Tan, Mark R. Lackner, Stuart K. Kim
1998171
10
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Molecular Cancer Therapeutics ·Georgia Hatzivassiliou, Bonnie Liu, Carol O’Brien, Jill M. Spoerke, Klaus P. Hoeflich, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Huifen Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John G. Moffat, Marcia Belvin, Mark R. Lackner
2012155
11
Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Clinical Cancer Research ·Jill M. Spoerke, Carol O’Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner
2012149
12
Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
Cancer Research ·Klaus P. Hoeflich, Sylvia Herter, Janet Tien, Leo Lap-Yan Wong, Leanne Berry, Jocelyn Chan, Carol O’Brien, Zora Modrušan, Somasekar Seshagiri, Mark R. Lackner, Howard M. Stern, Edna F. Choo, Lesley Murray, Lori S. Friedman, Marcia Belvin
2009144
13
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Future Oncology ·Mark R. Lackner, Timothy R. Wilson, Jeff Settleman
2012121
14
miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast CancerA presentation from the Keystone Symposium on Epithelial Plasticity and Epithelial to Mesenchymal Transition, Vancouver, Canada, 21 to 26 January 2011. This Presentation also complements the Science Signaling Research Article by Stinson et al. published 14 June 2011.
Science Signaling ·Susanna Stinson, Mark R. Lackner, Alex Adai, Nancy Yu, Hyojin Kim, Carol O’Brien, Jill M. Spoerke, Suchit Jhunjhunwala, Zachary Boyd, Thomas Januario, Robert Newman, Yue Peng, Richard Bourgon, Zora Modrušan, Howard M. Stern, Søren Warming, Frédéric J. de Sauvage, Lukas C. Amler, Ru‐Fang Yeh, David Dornan
2011118
15
Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy
Clinical Cancer Research ·Jiping Zha, Mark R. Lackner
2010112
16
Genetic Analysis of the Caenorhabditis elegans MAP Kinase Gene mpk-1
Genetics ·Mark R. Lackner, Stuart K. Kim
199899
17
Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer
Cancer Research ·Carol O’Brien, Guy Cavet, Ajay Pandita, Xiaolan Hu, Lauren E. Haydu, Sankar Mohan, Karen Toy, Celina Sanchez Rivers, Zora Modrušan, Lukas C. Amler, Mark R. Lackner
200888
18
Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer
Clinical Cancer Research ·Lisa Ryner, Yinghui Guan, Ron Firestein, Yuanyuan Xiao, Younjeong Choi, Christina Rabe, Shan Lu, Eloisa Fuentes, Ling‐Yuh Huw, Mark R. Lackner, Ling Fu, Lukas C. Amler, Carlos Bais, Yulei Wang
201586
19
Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Molecular Cancer Therapeutics ·Jiping Zha, Carol O’Brien, Heidi Savage, Ling‐Yuh Huw, Fiona Zhong, Leanne Berry, Gail D. Lewis Phillips, Elizabeth Luis, Guy Cavet, Xiaolan Hu, Lukas C. Amler, Mark R. Lackner
200966
20
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
Oncogenesis ·L-Y Huw, Carol O’Brien, Ajay Pandita, S. Mohan, Jill M. Spoerke, Shan Lu, Yulei Wang, Garret M. Hampton, Timothy R. Wilson, Mark R. Lackner
201366

About Mark R. Lackner

Mark R. Lackner is a scholar working on Molecular Biology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 82 papers that have together received 4.4k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (23 papers), PI3K/AKT/mTOR signaling in cancer (20 papers), Lung Cancer Treatments and Mutations (12 papers), Cancer Cells and Metastasis (7 papers), HER2/EGFR in Cancer Research (7 papers), Epigenetics and DNA Methylation (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). The work is most often cited by research in Aging (365 citations), Cancer Research (1.5k citations), Oncology (1.8k citations), Molecular Biology (2.6k citations) and Pulmonary and Respiratory Medicine (988 citations). Mark R. Lackner has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Lukas C. Amler, Carol O’Brien, Jill M. Spoerke, Stuart K. Kim, Garret M. Hampton, Elizabeth A. Punnoose, Heidi Savage, Timothy R. Wilson, Lori S. Friedman and Jiping Zha. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, Journal of Clinical Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo NucíforoBreakdown of academic impact, for papers by Marta Pàez‐RibesBreakdown of academic impact, for papers by Spencer J. CollisBreakdown of academic impact, for papers by Simone PetersenBreakdown of academic impact, for papers by Hirotaka OsadaBreakdown of academic impact, for papers by Caterina NardellaBreakdown of academic impact, for papers by Frank StegmeierBreakdown of academic impact, for papers by Nicholas A. WillisBreakdown of academic impact, for papers by Igor GarkavtsevBreakdown of academic impact, for papers by Kim L. Mercer